Amneal Pharmaceuticals (AMRX) Earnings Date, Estimates & Call Transcripts $8.50 +0.29 (+3.48%) As of 02:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Amneal Pharmaceuticals Earnings Summary Amneal Pharmaceuticals announced Q2 2025 earnings on August 5, 2025, reporting an EPS of $0.23, which topped the consensus estimate of $0.17 by $0.06. With a trailing EPS of $0.01 and a P/E Ratio of 851.35, Amneal Pharmaceuticals' earnings are expected to grow 13.21% next year, from $0.53 to $0.60 per share. Consensus EPS (Aug. 5) $0.17 Actual EPS (Aug. 5) $0.23 Beat By $0.06 Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)Slide DeckFull Screen Slide DeckPowered by Get Amneal Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amneal Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAMRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AMRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Amneal Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $0.53 EPSNext Year EPS Consensus Estimate $0.60 EPS Amneal Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025$0.17$0.23+$0.06$0.07--5/2/2025Q1 2025$0.14$0.19+$0.05$0.04$714.78M$695.42M2/28/2025Q4 2024$0.15$0.12 -$0.03-$0.10$708.21M$730.52M8/9/2024Q2 2024$0.11$0.15+$0.04$0.28$657.43M$701.78M5/3/2024Q1 2024$0.08$0.12+$0.04$0.54$623.08M$659.19M3/1/2024Q4 2023$0.05$0.12+$0.07$0.64$630.67M$616.98M11/7/2023Q3 2023$0.10$0.17+$0.07$0.28$613.74M$620.04M Amneal Pharmaceuticals Earnings - Frequently Asked Questions When did Amneal Pharmaceuticals announce their last quarterly earnings? Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earning data on Tuesday, August 5, 2025. Learn more on AMRX's earnings history. What guidance has Amneal Pharmaceuticals issued on next quarter's earnings? Amneal Pharmaceuticals issued an update on its FY 2025 earnings guidance on Tuesday, August, 5th. The company provided EPS guidance of 0.700-0.750 for the period, compared to the consensus EPS estimate of 0.705. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion. Did Amneal Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Amneal Pharmaceuticals (NASDAQ:AMRX) reported $0.23 earnings per share (EPS) to beat the analysts' consensus estimate of $0.17 by $0.06. Learn more on analysts' earnings estimate vs. AMRX's actual earnings. How can I listen to Amneal Pharmaceuticals' earnings conference call? The conference call for Amneal Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Amneal Pharmaceuticals' conference call transcript? The conference call transcript for Amneal Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Amneal Pharmaceuticals generate each year? Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded annual revenue of $2.79 billion. How much profit does Amneal Pharmaceuticals generate each year? Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded net income of -$116.89 million. AMRX has generated $0.01 earnings per share over the last four quarters. What is Amneal Pharmaceuticals' price-to-earnings ratio? Amneal Pharmaceuticals (NASDAQ:AMRX) has a trailing price-to-earnings ratio of 851.35 and a forward price-to-earnings ratio of 16.03. What is Amneal Pharmaceuticals' EPS forecast for next year? Amneal Pharmaceuticals' earnings are expected to grow from $0.53 per share to $0.60 per share in the next year, which is a 13.21% increase. More Earnings Resources from MarketBeat Related Companies BridgeBio Pharma Earnings Verona Pharma PLC American Depositary Share Earnings Blueprint Medicines Earnings Roivant Sciences Earnings Legend Biotech Earnings Elanco Animal Health Earnings Revolution Medicines Earnings Rhythm Pharmaceuticals Earnings Nuvalent Earnings TG Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Dutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a RallyRivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline This page (NASDAQ:AMRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
